• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Canagliflozin (Type 2 Diabetes) - Analysis and Forecasts to 2020 Product Image

Canagliflozin (Type 2 Diabetes) - Analysis and Forecasts to 2020

  • Published: January 2012
  • 41 pages
  • GlobalData

Canagliflozin (Type 2 Diabetes) – Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Canagliflozin (Type 2 Diabetes) – Analysis and Forecasts to 2020” provides Canagliflozin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU% and Japan (seven major markets)
- Analysis and review of Canagliflozin
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Diabetes
2.2 Epidemiology
2.2.1 Prevalence
2.2.2 Mortality
2.3 Etiology and Risk Factors
2.3.1 Obesity
2.3.2 Sedentary Lifestyle
2.3.3 Family History and Genetics
2.3.4 Ethnicity
2.3.5 Old Age
2.4 Economic Impact of Diabetes
2.5 GlobalData Report Guidance
3 Type 2 Diabetes: Market Characterization
3.1 Type 2 Diabetes Market
3.2 Type 2 Diabetes Market Forecasts
3.3 Type 2 Diabetes Market: Drivers and Restraints
3.3.1 Drivers
3.3.2 Restraints
4 Classification of Diabetes
4.1 Types of Diabetes
4.1.1 Type 1 Diabetes
4.1.2 Type 2 Diabetes
4.1.3 Gestational Diabetes
4.2 Diabetes Complications
4.2.1 Cardiovascular Disease
4.2.2 Nephropathy
4.2.3 Neuropathy
4.2.4 Amputation
4.2.5 Retinopathy
5 Evolution of Anti-Diabetic Treatments
6 Medications
6.1 Insulin
6.2 Oral Medications
6.2.1 Sulfonylureas (SUR)
6.2.2 Biguanides (BGDs)
6.2.3 Alpha-Glucosidase Inhibitors (AGI)
6.2.4 Meglitinides
6.2.5 Thiozolidinediones (TZDs)
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors
6.2.7 Oral Combination Therapy
6.3 Other Injectionable Medications
6.3.1 Pramlintide
6.3.2 Exenatide
6.4 Market Share as per Classes in Type 2 Diabetes
7 Canagliflozin
7.1 Introduction
7.2 Mechanism of Action
7.3 Clinical Studies
7.3.1 A Phase II Trial Evaluating Canagliflozin Vs Januvia for the Treatment of NIDDM Patients
7.3.2 A Phase III Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Canagliflozin Compared with Amaryl for the Treatment of Type 2 Diabetes
7.3.3 A Phase III Clinical Trial Evaluating Canagliflozin as a Monotherapy in Type 2 Diabetes Non Insulin Diabetes Mellitus Patients
7.4 Factors Affecting Sales of Canagliflozin
7.4.1 Emergence of SGLT2 inhibitors
7.4.2 No Weight Gain
7.5 Drug Evaluation
7.5.1 Drug Risk Benefit Score
7.5.2 Intensity of Competition
7.6 Sales Forecasts
7.6.1 Dosing
7.6.2 Market Penetration
7.6.3 Annual Cost of Therapy
7.6.4 Sales Projections of Canagliflozin
8 Diabetes Market: Appendix
8.1 Market Definitions
8.2 List of Abberiviations
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasting
8.3.4 Number of patients approved to take the drug
8.3.5 Net Penetration of Drug
8.3.6 Net Annual Dosing
8.3.7 Annual Cost of Therapy
8.4 Drug Sales Estimates Model
8.5 Contact Us
8.6 Disclaimer
8.7 Sources

1.1 List of Tables
Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010
Table 4: Type 2 Diabetes, World, Major Marketed Drugs By Sales ($m), 2010
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III Clinical Trails
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030
Table 7: Overweight-, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005
Table 8: Diabetes Drugs Evolution
Table 9: Drug Risk Benefit Score (DRB), Canagliflozin
Table 10: Canagliflozin, Type 2 Diabetes, Global, Sales Forecasts ($m), 2013–2020
Table 11: Canagliflozin, Type 2 Diabetes, The US, Sales Forecasts ($m), 2013–2020
Table 12: Canagliflozin, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2013–2020
Table 13: Canagliflozin, Type 2 Diabetes, France, Sales Forecasts ($m), 2013–2020
Table 14: Canagliflozin, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2013–2020
Table 15: Canagliflozin, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2013–2020
Table 16: Canagliflozin, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2013–2020
Table 17: Canagliflozin, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2016–2020

1.2 List of Figures
Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030
Figure 3: Diabetes, World, Mortality, 2010
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010–2020
Figure 6: Mechanism of Action of Sulfonylureas
Figure 7: Mechanism of Action of Biguanide, Thiozolidinediones, Alpha-Glucosidase Inhibitors
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors
Figure 9: Mechanism of Action of Thiozolidinediones
Figure 10: Mechanism of Action of DPP IV Inhibitors
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010
Figure 12: Canagliflozin, Type 2 Diabetes, Global, Sales Forecasts ($m), 2013–2020
Figure 13: Canagliflozin, Type 2 Diabetes, The US, Sales Forecasts ($m), 2013–2020
Figure 14: Canagliflozin, Type 2 Diabetes, The UK, Sales Forecasts ($m), 2013–2020
Figure 15: Canagliflozin, Type 2 Diabetes, France, Sales Forecasts ($m), 2013–2020
Figure 16: Canagliflozin, Type 2 Diabetes, Germany, Sales Forecasts ($m), 2013–2020
Figure 17: Canagliflozin, Type 2 Diabetes, Italy, Sales Forecasts ($m), 2013–2020
Figure 18: Canagliflozin, Type 2 Diabetes, Spain, Sales Forecasts ($m), 2013–2020
Figure 19: Canagliflozin, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2016–2020
Figure 20: Canagliflozin, Type 2 Diabetes, Sales Distribution by Country (%), 2020
Figure 21: Patients Approved for the Drug

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos